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Abstract 
Background: The Mediterranean diet (MeD) plays a key role in the prevention of obesity. Among the genes involved 
in obesity, the Fat mass and obesity-associated gene (FTO) is one of the most known, but its interaction with MeD 
remained uncertain so far.
Methods: We carried out a study on a sample of 188 Italian subjects, analyzing their FTO rs9939609 alleles, and the 
difference in body composition between the baseline and a 4-weeks nutritional intervention. The sample was divided 
into two groups: the control group of 49 subjects, and the MeD group of 139 subjects.
Results: We found significant relations between MeD and both variation of total body fat (ΔTBFat) (p = 0.00) and 
gynoid body fat (p = 0.04). ∆TBFat (kg) demonstrated to have a significant relation with the interaction diet-gene 
(p = 0.04), whereas FTO was associated with the variation of total body water (p = 0.02).
Conclusions: MeD demonstrated to be a good nutritional treatment to reduce the body fat mass, whereas data 
about FTO remain uncertain. Confirming or rejecting the hypothesis of FTO and its influence on body tissues during 
nutritional treatments is fundamental to decide whether its effect has to be taken into consideration during both 
development of dietetic plans and patients monitoring.
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Background
The Mediterranean diet (MeD) is considered one of the 
healthiest dietetic pattern in the world [1]. It is charac-
terized by a high consumption of olive oil, fish, fruits, 
legumes, vegetables, unrefined cereals, a moderate con-
sumption of wine and dairy products, and a low con-
sumption of non-fish meat products [2]. According to 
several studies, thanks to its peculiar distribution of 
macro and micronutrients, this dietary model plays a 
key role in the prevention of a wide number of chronic 
diseases, such as cardiovascular diseases (CDVs), dia-
betes and metabolic syndrome [3–5], making an impor-
tant contribution to the weight loss, especially if it is 
associated with energy restriction and constant physi-
cal activity [6]. In view of above, it is worth recalling 
that this dietary models can also prevent and treat obe-
sity [7], a disease, usually classified through that pro-
vides alterations in body composition like abnormal or 
excessive fat accumulation [8–10]. This medical condi-
tion is caused by a several numbers of co-factors, such 
as psychological problems, sedentary life and incorrect 
dietetic habits [11, 12], and it is an important risk fac-
tor for all those aforementioned diseases fought by the 
Mediterranean diet [13]. Therefore, in this context, it is 
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understandable why this dietary model plays a key role 
in the health protection.
Nevertheless, independently from the dietetic hab-
its, also genetics play a key role in the development 
of obesity [14]. In the human genome, a several num-
ber of genes are involved in the obesity, and Fat mass 
and obesity-associated gene (FTO) is surely one of the 
most important. This gene, widely expressed in several 
fetal and adult tissues, is located on chromosome 16 
(16q12.2), and encodes for the enzyme alpha-ketoglu-
tarate-dependent dioxygenase [15]. This enzyme is 
implied in the regulation of both the control of adipo-
cyte thermogenesis and differentiation, contributing 
considerably to the body fat accumulation [16]. Fur-
thermore, it contributes to the regulation of energy 
homeostasis and metabolic rate [17], increasing also 
the food intake [18]. Finally, among the other activi-
ties, is implicated in the repairs of alkylated DNA and 
RNA via oxidative demethylation [19]. Among the sev-
eral variants of this gene, FTO rs9939609 is one of the 
best-know. It is located in the first intron of the gene 
and, in 2007, it was for the first time associated with 
the body mass [20]. Subsequently, further studies dem-
onstrated that the allele A of FTO rs9939609 is related 
to both a higher body mass index and body circumfer-
ences [21, 22], and, among different ethnicities, also 
Italian population demonstrated the same results [23]. 
Furthermore, this SNP is included among the genetic 
etiological factors in the development of both meta-
bolic syndrome and Type-2 diabetes [24, 25], and allele 
A was also associated with a higher fat and lean mass 
[26, 27]. In a PREDIMED substudy, it was observed 
that homozygous subjects for A allele had the highest 
baseline body weight, but also the lowest body weight 
gain after 3  years of Mediterranean-style intervention, 
compared to TT genotype. However, no interaction 
between nutritional intervention and the polymor-
phism was found [28, 29]. On the other hand, Ortega-
Azorín et  al. [30] demonstrated consistent gene-diet 
interactions between FTO rs9939609 and Melanocor-
tin-4 Receptor (MC4R) rs17782313 genes and to the 
Mediterranean diet adherence in the type 2 diabetes 
risk. The same effect was observed in obese phenotypes 
in Iranian population. Subjects with minor allele carri-
ers of FTO variants rs9939973, rs8050136, rs1781749, 
and rs3751812 had a lower risk of obesity when they 
had a higher Mediterranean dietary score compared to 
wild-type homozygote genotype carriers [31].
In the light of these observations the objective of this 
study was to investigate about the possible influence of 
FTO rs9939609 variant on both weight loss and modifi-
cation of body composition in Italian subjects, after hav-
ing followed a 4-weeks dietetic intervention based on the 
Mediterranean model, in order to see if this polymor-
phism could influence the response to a specific dietary 
treatment.
Methods
Study design and subjects
The study was carried out between January 2017 and 
March 2018 at the Section of Clinical Nutrition and 
Nutrigenomics, Department of Biomedicine and Pre-
vention of the University of Rome Tor Vergata. The ini-
tial sample recruited was composed of 300 subjects, 
who came up for the first time for a nutritional-medical 
checkup at the Clinical Nutrition and Nutrigenomic Sec-
tion at the University of Rome Tor Vergata. To be eligible, 
each individual had to belong to the Caucasian race, to be 
Italian and older than 16 years old. Furthermore, for each 
subject, the medical assessment was evaluated before and 
after the application of prescribed nutritional treatments. 
We have pooled the sample in two groups, 150 subjects 
followed, for a period of 4  weeks, a Mediterranean diet 
(MeD), whereas the remaining 150 were allocated, within 
the same period, in the control group (CTR). The rand-
omization and allocation of the study participants was 
performed using the IBM SPSS 21.0 for Windows (IBM 
Corp., Armonk, NY, USA). All the individuals included 
in the study approved their participation by learning 
and signing the informed consent, which was drawn up 
in accordance with the commissariat of the Ethics Com-
mittee of Medicine, University of Rome Tor Vergata and 
with the Helsinki Declaration of 1975 as revised in 1983. 
Trial Registration: this protocol has been registered by 
ClinicalTrials.gov, ID: NCT01890070.
Anthropometric, bioimpendance analysis, and dual‑energy 
X‑ray absorptiometry
After a 12-h overnight fasting, all subjects under-
went anthropometric evaluation. All the individu-
als were instructed to take off their clothes and shoes 
before undergoing the measurements. Body weight 
was assessed with balance scale to the nearest 0.1  kg 
(Invernizzi, Rome, Italy). Height was evaluated using 
a stadiometer (Invernizzi, Rome, Italy) to the near-
est 0.1  cm. BMI was calculated using the formula 
BMI = body weight/height2
(
kg/m2
)
 . Waist, hip, neck 
and abdomen circumferences were assessed using a flex-
ible steel metric tape to the nearest 0.5 cm, according to 
the International Society for the Advancement of Kin 
anthropometry protocol and National Institute of Health 
Guidelines [32].
Body composition analysis was performed using both 
dual-energy X-ray absorptiometry (DXA) (I-DXA, GE 
Medical Systems, Milwaukee, WI, USA) and bioelectri-
cal impedance analysis (BIA 101S, Akern/RJL Systems, 
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Pontassieve, Florence, Italy). DXA was carried out to 
evaluate total, android and gynoid, of fat mass per-
centage (FM%), fat mass (FM) and lean mass (LM) in 
Kg. Total fat mass percentage (Total FM%) was calcu-
lated as Total body fat mass (Total FM) divided by the 
total mass of all tissues (Total LM), including the total 
body bone (TBBone), as the following: Total FM% =
(Total FM/(Total FM + Total LM + TBBone)) × 100 
[33]. Bioelectrical impedance analysis was carried out 
to evaluate resistance (R), reactance (Xc), phase angle 
(PA), hydration, exchange Na/K, total body water (TBW), 
extracellular water (ECW), intracellular water (ICW), 
body cell mass (BCM), body cell mass index (BCMI). 
Finally, waist/hip ratio (WHR) was analyzed and evalu-
ated according to the clinical risk thresholds, equivalent 
to WHR > 0.9 for men and WHR > 0.85 for women [34].
According to De Lorenzo et  al. [10], we catego-
rized our population based on phenotype classification 
through BMI and TBFat% as follows: underweight (UW) 
(BMI < 18.50); normal-weight (NW) (18.50 ≤ BMI < 25 
or BMI ≥ 25 but Total TBFat% lower than 30% for 
women and 25% for men); normal weight obese 
(NWO) (18.50 ≤ BMI < 25 and TBFat% higher than 
30% for women and 25% for men); Preobese (PreOb) 
(25 ≤ BMI < 30 and TBFat% higher than 30% for women 
and 25% for men); Obesity I (30 ≤ BMI < 35); Obesity II 
(35 ≤ BMI < 40); Obesity III (BMI ≥ 40).
DNA isolation and RTq‑PCR analysis
The phenol–chloroform extraction described by Barker 
et al. [35] was used to extract the Genomic DNA, which 
was collected, in turn, via saliva swab. To prepare the 
gDNA for the genotyping, a two allele-specific fluores-
cent probe including a PCR primer pair (TaqMan SNP 
Genotyping Assays, Life Technologies, CA, USA) and a 
master mix including dNTPs and Taq DNA Polymerase 
(TaqPath ProAmp Master mix Life Technologies, CA, 
USA) were used. The FTO rs9939609 context sequence 
was the following: GGT TCC TTG CGA CTG CTG TGA 
ATT T [A/T] GTG ATG CAC TTG GAT AGT CTC TGT T. 
Finally, SNP genotyping assessment was executed using 
a Real-Time PCR analysis (Applied Biosystems StepO-
nePLus Real-Time PCR, Life Technologies, CA, USA), 
according to the manufacturer’s instructions.
Dietary assessments
At baseline subjects food intake was assessed with a 3-day 
diet records completed for 2  weekdays and 1  weekend 
day [36]. Participants were instructed to record weight 
and/or measures of foods and beverages consumed. Diet 
records were reviewed to clarify the amounts of foods 
ingested. The estimated intake of macronutrients was 
calculated by using Dietosystem dietary software (DS 
Medica S.r.l., Milan, Italy).
Dietary intervention
In MeD intervention, an isocaloric Mediterranean diet 
in which the daily macronutrients intake was distributed 
as follows: 55% of carbohydrates, 20% of protein (> 50% 
of vegetable derivation), < 25% of lipids (on total daily 
energy intake: saturated fat < 10%, 6–10% polyunsatu-
rated fatty acids (PUFA), n-6/n-3 PUFA ratio of 3:1, 15% 
of monounsaturated fatty acids (MUFA); < 1% trans-fatty 
acids) and 25 g of fiber.
For each subject, the energy intake was calculate 
according to the estimation of the rest energy expendi-
ture (REE), which was determined using the Weir 
Formula:
 [37], in which  VO2 and  VCO2 were calculated as follows:
VO2 = Total LM DXA (kg) × 5 for females,  VO2 = Total 
LM DXA (kg) × 4.5 for males and  VCO2 = VO2 × 0.85 
[38].
The REE was multiplied for the proper physical activity 
level (PAL) according to the WHO and Food and Agri-
culture Organization of the United Nations (FAO) rec-
ommendations [39].Conversely, in the control group, the 
subjects did not follow any specific diet, but they have 
received general recommendations on healthy nutritional 
habit and were only monitored, even though also for 
these subjects REE and the energy intake were evaluated 
as aforementioned.
Analysis of blood sample
Blood samples, taken after a 12-h overnight fast, were 
collected in sterile tubes containing EDTA  (Vacutainer®) 
and put on ice. Plasma, after being separated by cen-
trifugation (1600 rpm, at 4  °C for 10 min), was removed, 
aliquoted and stored at − 80  °C. All clinical chemistry 
analyses, except serum lipid plasma and glucose analy-
sis, were performed using an  ADVIA®1800 Chemis-
try System (Siemens Healthcare), following standard 
procedures [40]. Plasma glucose concentrations were 
measured through the glucose oxidase method and auto-
mated glucose analyzer (COBAS INTEGRA 400, Roche 
Diagnostics, Indianapolis, IN, USA); serum lipid profile 
constituents were evaluated by standard enzymatic col-
orimetric techniques (Roche143 Modular P800, Roche 
Diagnostics, Indianapolis, IN, USA).
Statistical analysis
The SNP-HWE program was used to calculate the Hardy-
Weinberg equilibrium (HWE) for FTO rs9939609, and 
REE =
[(
3.94 × VO2
)
+
(
1.106× VCO2
)]
× 1.44
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the result was tested using the χ2 analysis [41]. To analyze 
the sample, the subjects were divided into carrier/non-
carrier (carrier for A allele vs homozygous T) and into 
MeD and CTR (Mediterranean diet vs Control group). 
The Kolmogorov–Smirnov test was used to analyze 
the distribution of variables, and data were normalized 
according to Z-score transformation. T-test analysis was 
performed between A carriers and TT genotype at base-
line, as well as ANOVA one way analysis, adjusted with 
Bonferroni post hoc analysis, between the genotype/
treatment groups in order to see significant differences 
among groups (p < 0.05). Change (Δ) in body weight 
(kg), BMI, neck, waist, abdomen and hip circumferences 
(cm), WHR, R, Xc, BCM (kg), Na/K, TBW (L), ECW (L), 
ICWb (L), BCMI, Android Bfat (%), Gynoid Bfat (%), 
TBFat (%), Android Bfat (Kg), Gynoid Bfat (Kg), TBFat 
(Kg), Android BLean (kg), Gynoid BLean (kg), TBLean 
(kg) and REE were calculated by subtracting measure-
ments recorded before the beginning of the nutritional 
treatments, from the measurement recorded after the 
completion of the nutritional intervention. In order to 
compare the differences in mean of the aforementioned 
values, respectively for A carriers and TT genotype, gene, 
diet and gene–diet interaction analyses were carried out 
using a Generalized Linear Model (linear GLM), adjusted 
for sex and age. TBFat (kg) was selected as a parameter 
to calculate minimum sample size. The minimum sam-
ple size was calculated using a two-tailed one-sample 
Student’s t-test, considering:(i) TBFat to be detected 
between baseline and MED|δ| = − 3.86 kg; (ii) SD of the 
paired differences SD = 6.38 kg, (iii) type I error probabil-
ity α = 0.05 and power 1 − β = 0.95. The result was a min-
imum sample size of 36 for MED and 12 for CTR group. 
Significance was set as p < 0.05 and the statistical analysis 
was performed using IBM SPSS 21.0 for Windows (IBM 
Corp., Armonk, NY, USA).
Results
Population characteristics
The enrolled 300 subjects met the inclusion criteria and 
nobody declined to participate. Subjects were equally 
randomized allocated in MeD group and CTR group. 
During this clinical trial, 11 subjects from MeD group 
and 101 subjects from CTR group abandoned the study 
as specified in Fig.  1. In fact, 5 subjects form the MeD 
group abandoned the study for poor weight loss results 
and 6 subjects for poor adherence to the diet therapy. 
On the other hand, in the CTR group 101 subjects aban-
doned the study since they did not see any kind of health 
benefits or improvement. The final sample analyzed con-
sisted of 188 patients, divided as follow: 139 subjects in 
MeD group and 49 for CTR group. These patients suc-
cessfully participated and completed the study protocol.
In our sample, the HWE was respected (p > 0.05). The 
comprehensive description of the whole sample popula-
tion at baseline can be seen in Table  1. All results were 
stated as mean and standard deviation. The average age 
of the individuals was 46.83 ± 15.01 years, 62.2% females 
and 37.8% males (Table  1). According to the statisti-
cal analysis, at baseline, carriers and no carriers differs 
significantly only for age, diastolic blood pressure, R, 
basophils count and unsaturated fatty acids and polyun-
saturated fatty acids intake (p < 0.05) (Table 1). Genotype 
frequencies of our individuals (TT: 0.310; AA: 0.190; AT: 
0.500) are similar to the ones shown in TSI population 
(TT: 0.327, AA: 0.252, AT: 0.421), and the same result 
was demonstrated about the allele frequencies, simi-
lar between TSI (T: 0.537; A: 0.463) and our sample (T: 
0.550; A: 0.450) (Table  2). The average BMI of the sub-
ject was 29.39 ± 6.99, and the average Total FM (kg) was 
37.3 ± 9.76. Finally, in order to have a detailed description 
of the sample, in Table 3 the individuals, at the baseline, 
were divided by genotype and categorized according to 
phenotype classification.
At baseline, differences were highlighted between TT 
genotype and A carriers for age, DBP, BCM (kg), baso-
phils (1000/μL), unsaturated fatty acids (g) and polyun-
saturated fatty acids (g) intake (p < 0.05).
Among the genotype/treatment groups significances 
were found for SBP between control group TT geno-
type and Med group TT genotype, DBP between control 
group TT genotype and the other groups (control group 
A carriers, Med group TT genotype and Med group A 
carriers) and neck circumference between control group 
TT genotype and Med group A carriers, control group A 
carriers and Med group TT genotype and Med group A 
carriers (p < 0.05). No other statistical significance were 
found at baseline between groups.
Influences of FTO rs9939609 and nutritional intervention 
on BMI, body composition and metabolism
In this study, the GLM analysis was used to demonstrate 
the statistical significance between FTO rs9939609 car-
riers A and TT genotype together with the nutritional 
intervention.
According to the results, TBFat (kg) decreases depend-
ently both of the nutritional intervention  (pD = 0.00) 
and the interaction gene-diet  (pGD = 0.04), showing a 
significant difference between MeD and CTR, but also 
suggesting a potential role, even though not statistically 
significant, of FTO rs9939609  (pG = 0.06), since A car-
rier CTR gained weight sensibly more than TT genotype 
CTR, and A carrier MeD lost more weight than TT geno-
type MeD (MeD/TT genotype = − 3.59 ± 4.78; MeD/A 
carriers = − 3.97 ± 6.97; CTR/TT genotype = 1.93 ± 5.54; 
CTR/A carriers = 6.11 ± 9.60) (Table  4). Furthermore, 
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MeD group, regardless of FTO rs9939609  (pG = 0.70; 
 pGD = 0.32) (Table  4), lost a higher amount of Gynoid 
BFat (%) compared to CTR (p = 0.04) (MeD/TT geno-
type = − 2.94 ± 5.14; MeD/A carriers = − 1.67 ± 3.51; 
CTR/TT genotype = 0.03 ± 1.26; CTR/A carri-
ers = − 0.42 ± 1.74) (Table 4).
The bioelectrical impedance analysis highlighted 
that TBW, was significantly reduced in A carriers com-
pared to TT genotype  (pG = 0.02), independently 
of nutritional intervention  (pD = 0.48;  pGD = 0.47) 
(MeD/TT genotype = − 0.83 ± 1.63; MeD/A carri-
ers = − 1.88 ± 4.35; CTR/TT genotype = 0.70 ± 3.04; 
CTR/A carriers = − 1.75 ± 3.28) (Table  4). All the other 
results were not statistically significant (p > 0.05).
Discussion
Among the different dietetic patterns, the Mediterranean 
diet is surely one of the healthiest in the world [1]. In fact, 
several studies demonstrated its capability to prevent 
different cardiovascular and metabolic diseases, such as 
CONSORT 2010 Flow Diagram
Assessed for eligibility (n=300)
Excluded  (n=0)
♦ Not meeting inclusion criteria (n=0)
♦ Declined to participate (n=0)
♦ Other reasons (n=0)
Analysed  (n=139)
♦ Excluded from analysis (n=0)
Lost to follow-up (patients do not see improvement) (n=5)
Discontinued intervention (patients do not follow the 
treatment for personal reasons) (n=6)
Allocated to intervention (n=150)
♦ Received allocated intervention (n=150)
♦ Did not receive allocated intervention (n=0)
Lost to follow-up (patients do not see improvement) 
(n=101)
Discontinued intervention (give reasons) (n=0)
Allocated to intervention (n=150)
♦ Received allocated intervention (n=150)
♦ Did not receive allocated intervention (n=0)
Analysed  (n=49)
♦ Excluded from analysis (n=0)
Allocation
Analysis
Follow-Up
Randomized (n=300)
Enrollment
Fig. 1 Study design
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Table 1 Descriptive characteristics of study population
Total TT genotype A carriers
Age (years) 46.83 (± 15.01) 43.29 (± 16.04)a 48.36 (± 14.34)a
Systolic BP (mm Hg) 126.14 (± 17.03) 127.96 (± 20.80) 125.42 (± 15.41)
Distolic BP (mm Hg) 86.62 (± 19.45) 94.42 (± 23.64)a 83.30 (± 16.48)a
Height (cm) 165.85 (± 9.04) 166.17 (± 9.52) 165.71 (± 8.86)
Weight (kg) 80.9 (± 21.14) 77.83 (± 20.47) 82.23 (± 21.36)
BMI (kg/m2) 29.39 (± 6.99) 28.09 (± 6.68) 29.95 (± 7.08)
Neck circumference (cm) 39.47 (± 4.34) 38.71 (± 3.80) 39.70 (± 4.48)
Waist circumference (cm) 90.95 (± 16.38) 87.63 (± 16.45) 92.23 (± 16.25)
Abdomen circumference (cm) 103.31 (± 15.75) 98.71 (± 14.81) 104.70 (± 15.85)
Hip circumference (cm) 106.49 (± 12.09) 103.38 (± 9.84) 107.68 (± 12.68)
WHR 0.85 (± 0.11) 0.84 (± 0.11) 0.86 (± 0.11)
R 505.78 (± 96.34) 538.67 (± 83.75)a 492.62 (± 98.31)a
Xc 55.56 (± 13.15) 57.14 (± 10.34) 54.93 (± 14.13)
PA 6.42 (± 1.33) 6.24 (± 1.11) 6.49 (± 1.41)
BCM (kg) 30.27 (± 8.37) 28.03 (± 7.16)a 31.18 (± 8.68)a
Na/K 0.94 (± 0.16) 0.97 (± 0.12) 0.93 (± 0.17)
BCM (%) 55.75 (± 6.97) 54.46 (± 4.92) 56.30 (± 7.66)
TBW (L) 40.36 (± 9.52) 38.44 (± 8.60) 41.14 (± 9.81)
ECW (L) 17.76 (± 4.46) 17.23 (± 3.94) 17.97 (± 4.66)
ICW (L) 22.76 (± 6.45) 21.43 (± 5.62) 23.33 (± 6.73)
BCMI 12.5 (± 6.58) 11.68 (± 5.64) 12.83 (± 6.92)
Android FM% 43.19 (± 12.54) 42.18 (± 11.70) 43.55 (± 12.87)
Gynoid FM% 41.03 (± 10.93) 40.90 (± 10.32) 41.09 (± 11.21)
Total FM% 37.3 (± 9.76) 36.56 (± 8.83) 37.62 (± 10.15)
Android FM (kg) 3.13 (± 2.02) 2.84 (± 1.79) 3.25 (± 2.10)
Gynoid FM (kg) 5.45 (± 2.3) 5.15 (± 2.03) 5.57 (± 2.39)
Total FM (kg) 29.93 (± 14.88) 28.48 (± 13.80) 30.56 (± 15.33)
Android LM (kg) 3.25 (± 0.88) 3.31 (± 0.95) 3.23 (± 0.85)
Gynoid LM (kg) 6.88 (± 1.82) 6.92 (± 1.95) 6.86 (± 1.77)
Total LM (kg) 47.6 (± 11.03) 47.31 (± 11.69) 47.73 (± 10.80)
VO2 231.81 (± 46.56) 228.71 (± 46.22) 234.23 (± 46.14)
VCO2 197.04 (± 39.57) 194.40 (± 39.29) 199.10 (± 39.22)
REE 1628.52 (± 326.88) 1602.65 (± 322.62) 1647.16 (± 324.44)
Glycemia (mg/dL) 92.77 (± 15.81) 93.83 (± 15.11) 92.34 (± 16.19)
Insulin (μ/μmL) 8.23 (± 4.4) 6.80 (± 4.50) 9.08 (± 4.25)
Tot cholesterol (mg/dL) 197.87 (± 43.13) 185.36 (± 47.98) 202.34 (± 40.70)
HDL (mg/dL) 54.5 (± 15.86) 58.46 (± 16.82) 53.10 (± 15.40)
TG (mg/dL) 109.31 (± 50.71) 95.40 (± 49.41) 114.22 (± 50.61)
LDL (mg/dL) 122.21 (± 30.01) 111.17 (± 33.38) 126.05 (± 28.00)
GOT/AST (uL) 22.16 (± 9.05) 21.91 (± 12.63) 22.24 (± 7.64)
GPT/ALT (uL) 24.67 (± 12.5) 23.81 (± 12.92) 24.95 (± 12.44)
Basophils (1000/μL) 0.02 (± 0.03) 0.03 (± 0.03)a 0.02 (± 0.02)a
Basophils (%) 0.53 (± 0.36) 0.67 (± 0.48) 0.44 (± 0.20)
Eosinophils (1000/μL) 0.23 (± 0.37) 0.36 (± 0.64) 0.17 (± 0.10)
Eosinophils (%) 3.07 (± 2.01) 3.81 (± 2.87) 2.74 (± 1.40)
HCT (%) 41.87 (± 3.2) 41.83 (± 2.70) 41.89 (± 3.43)
Hemoglobin (g/dL) 14.11 (± 1.32) 14.05 (± 1.11) 14.14 (± 1.41)
Lymphocytes (1000/μL) 2.19 (± 1.06) 2.08 (± 0.57) 2.24 (± 1.22)
Lymphocytes (%) 32.75 (± 7.3) 33.08 (± 7.69) 32.62 (± 7.22)
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metabolic syndrome and type-2 diabetes [2, 4, 5]. Moreo-
ver, this type of dietetic model turns out to be fundamen-
tal both in preventing and treating the obesity [6, 42], 
which is becoming one of the most widespread medical 
condition in the world, since recent statistics demon-
strated that, by 2030, the 20% of the global adult popula-
tion will be obese, and the 38% will be overweight [43]. 
Nevertheless, also genetics plays an important role in the 
development of the obesity [14]. So far, a wide number 
of genes are associated with the body composition, and 
one of the most studies is certainly FTO. Several variants 
Table 1 (continued)
Total TT genotype A carriers
MCH (pg) 29.71 (± 2.1) 29.73 (± 1.52) 29.70 (± 2.32)
MCHC (g/dL) 33.66 (± 1.43) 33.74 (± 1.42) 33.64 (± 1.45)
MCV (fL) 88.3 (± 4.42) 88.98 (± 4.63) 87.82 (± 4.33)
Monocytes (1000/μL) 0.47 (± 0.18) 0.46 (± 0.15) 0.47 (± 0.19)
Monocytes (%) 7.29 (± 2.03) 7.21 (± 1.46) 7.32 (± 2.24)
Neutrophiles (1000/μL) 3.64 (± 1.15) 3.59 (± 1.04) 3.67 (± 1.25)
Neutrophiles (%) 56.12 (± 7.99) 55.69 (± 8.52) 56.44 (± 7.78)
Plateles (1000/μL) 205.83 (± 36.84) 210.17 (± 39.32) 202.94 (± 35.96)
RBC (million/μL) 4.74 (± 0.43) 4.68 (± 0.41) 4.78 (± 0.44)
RDW-CV 12.79 (± 3.74) 10.92 (± 3.45) 13.62 (± 3.60)
WBC (1000/μL) 7.21 (± 4) 7.79 (± 5.55) 6.86 (± 2.81)
ESR (mm) 31.03 (± 68.58) 36.00 (± 86.37) 29.14 (± 62.24)
Fibrinogen (mg/dL) 290.29 (± 168.28) 351.40 (± 85.57) 264.10 (± 193.31)
Uric acid (mg/dL) 8.84 (± 9.14) 10.64 (± 11.23) 8.14 (± 8.26)
CRP (mg/dL) 1.79 (± 3.13) 1.32 (± 2.04) 1.95 (± 3.45)
Kcal 1721.86 (± 731.69) 1730.05 (± 823.19) 1711.23 (± 636.34)
Proteins (g) 83.18 (± 27.04) 82.16 (± 35.01) 84.51 (± 12.22)
Proteins (%) 19.33 (± 3.95) 19.86 (± 4.60) 18.64 (± 3.00)
Carbohydrates (g) 223.05 (± 106.41) 209.86 (± 131.30) 240.19 (± 64.14)
Carbohydrates (%) 46.88 (± 7.63) 46.19 (± 8.43) 47.78 (± 6.78)
Simple carbohydrates (g) 75.83 (± 33.01) 75.06 (± 43.41) 76.82 (± 12.23)
Complex carbohydrates (g) 128.72 (± 55.39) 125.68 (± 64.34) 132.68 (± 44.16)
Lipids (g) 62.17 (± 26.78) 58.91 (± 30.67) 66.40 (± 21.54)
Lipids (%) 30.84 (± 6.64) 30.50 (± 5.76) 31.29 (± 7.95)
Total cholesterol (mg) 218.90 (± 90.23) 218.67 (± 106.36) 219.20 (± 69.40)
Saturated fatty acids (g) 17.02 (± 10.07) 15.84 (± 11.65) 18.55 (± 7.89)
Unsaturated fatty acids (g) 8.80 (± 4.07) 7.21 (± 3.72)a 10.87 (± 3.69)a
Monounsaturated fatty acids (g) 52.13 (± 132.35) 72.95 (± 176.00) 25.06 (± 8.58)
Polyunsaturated fatty acids (g) 9.11 (± 4.25) 7.21 (± 4.04)a 11.42 (± 3.39)a
Fiber (g) 22.63 (± 9.92) 20.50 (± 5.09) 25.39 (± 13.82)
Descriptive table of the overall study population. Data were reported as mean and standard deviation. Statistical significance (a) among A carriers and TT genotype 
groups at baseline were given to results with p < 0.05 through t-test analysis
BP blood pressure, BMI body mass index, WHR waist hip ratio, Xc reactance, R resistance, PA phase angle, BCM body cell mass, HYDR hydration, Na/K sodium–potassium 
exchange, TBW total body water, ECW extracellular water, ICW intracellular water, BCMI body cell mass index, BFat body fat, TBFat: total body fat, BLean body lean, 
TBLean total body lean, REE resting energy expenditure, HDL high-density lipoprotein, TG triglycerides, LDL low-density lipoprotein, GOT glutamic oxaloacetic 
transaminase, AST aspartate aminotransferase, GPT glutamate pyruvate transaminase, ALT alanine transaminase, HCT hematocrit, MCH mean corpuscular hemoglobin, 
MCHC mean corpuscular hemoglobin concentration, MCV mean corpuscular volume, RBC red blood cells, RDW-CV red blood cell distribution width, WBC white blood 
cells, ESR erythrocyte sedimentation rate, CRP C-reactive protein
Table 2 Study population allele and genotype frequencies 
for  FTO rs9939609 compared to  Tuscan Italians 
from Southern Europe (TSI)
Description of study population and genotype frequencies
FTO rs9939609
Allele frequency A T
 TSI 0.46 0.54
 Study population 0.45 0.55
Genotype frequency AA AT TT
 TSI 0.20 0.46 0.34
 Study population 0.19 0.50 0.31
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of this gene were associated with the BMI, and FTO 
rs9939609 is certainly one of the most known [44, 45]. In 
fact, its allele A is highly related with higher BMI [20, 46], 
fat and lean mass [26, 27]. On the contrary, for the time 
being, several studies demonstrated that, during a die-
tetic treatment, FTO rs9939609 do not seem to influence 
the weight loss [28, 47]. In view of above, we have con-
ducted this study in order to analyze whether and how 
FTO rs9939609 variant influence both weight loss and 
body composition in Italian patients, within a Mediter-
ranean dietetic treatment.
According to our results, TBW is highly influenced 
by FTO. In fact, analyzing the alteration of this value in 
each group (Table 4), it is possible to see that A carriers 
lost a higher quantity of body water compared to TT 
genotype (MeD/TT genotype = − 0.83 ± 1.63; CTR/TT 
genotype = 0.70 ± 3.04; MeD/A carriers = − 1.88 ± 4.35; 
CTR/A carriers = − 1.75 ± 3.28) (Table 4), whilst no dif-
ference due to MeD intervention was found. This result 
may be a confounding factor in the weight loss, since it 
influences the decreasing of both BMI and body weight 
during nutritional treatments, overestimating the effec-
tive fat mass loss. Analyzing the results of body compo-
sition evaluated via DXA, both dietetic treatment and 
interaction diet-gene influence the total body fat mass, 
whilst FTO alone did not demonstrate the same effect. 
Moreover, Gynoid BFat% declining was highly related 
to the dietetic therapy, confirming that MeD treat-
ment had an effect on body composition, confirming 
its capabilities, already demonstrated in several studies 
[48, 49], to reduce body fat, giving its important con-
tribution against all the diseases related to the body fat 
mass. In our sample, the difference between the two 
nutritional treatments is highly considerable, since 
both MeD groups lost weight in a similar manner. It is 
also important to highlight that, in our sample, FTO 
did not influence the outcome of the nutritional treat-
ment, thus confirming the results of previous studies 
[28, 50]. These results might mean that, during a die-
tetic therapy, this SNP should not be taken into consid-
eration, since it does not influence the outcome of both 
body composition and anthropometric measurements. 
However, the fact that also the interaction gene-diet 
had an effect on the TBFat suggests that, even though 
slightly, FTO might influence the outcome of the Medi-
terranean diet on this specific value, as previously pro-
posed by another study [51]. Nonetheless, analyzing 
our results, it can be assumed that this statistical signif-
icance may be given by the incredible amount of TBFat 
gained by the A carriers/CTR group, thus suggest-
ing an interesting role of this SNP in the development 
and preservation of body fat mass outside periods of 
nutritional therapies, as previously assumed by studies 
on murine models [18, 52]. Considering these results, 
we suggest that understanding whether and how FTO, 
along with other genes or alone, influence the fat mass 
loss during nutritional treatments could help us to draft 
better clinical pictures of patients, and prevent dif-
ficulties of weight loss due to genetic factors. Moreo-
ver, both nutritional treatment and FTO alleles did not 
influence the lean mass, which, in contrast to the fat 
mass, remained almost steady within the studied period 
in all the analyzed groups. Finally, according to the sta-
tistical significance, in our sample, FTO rs9939609 did 
not influence body circumferences, weight, and conse-
quently BMI. Nevertheless, even though in a non-sig-
nificant manner, analyzing the data in Table 4, it can be 
seen how A carriers subjects lost less weight compared 
to TT genotype, following a trend already noted [53], 
and leaving some doubt about the effective activities of 
this SNP during nutritional treatments.
Conclusions
To conclude, Mediterranean diet confirmed to be use-
ful in the prevention and treatment against obesity, since 
it demonstrated, in our sample, to reduce the body fat 
mass. On the contrary, data about FTO remain uncertain, 
and considering the importance of this SNP in the rela-
tion with BMI and body composition, further studies are 
needed to clarify definitely whether this SNP influences 
the outcome of the dietetic therapies. If FTO rs9939609 
demonstrated to influence the decreasing of body tissues 
during nutritional treatments, its effect should be taken 
into consideration during both development of dietetic 
plans and monitoring of patients.
Table 3 BMI distribution of  study population according 
to FTO rs9939609 variant
Frequencies of carrier and non-carrier subjects according to the BMI. UW 
(BMI < 18.50); NW (18.50 ≤ BMI < 25 or BMI ≥ 25 plus TBFat% < 30% females 
and < 25% M); NWO (18.50 ≤ BMI < 25 plus Total TBFat% ≥ 30% females 
and ≥ 25% males); PreOb (25 ≤ BMI < 30 plus TBFat% ≥ 30% females and ≥ 25% 
males); Ob I (30 ≤ BMI < 35); Ob II (35 ≤ BMI < 40); Ob III (BMI ≥ 40). BMI body mass 
index, UW underweight, NW normal-weight, NWO normal-weight obese, PreOb 
pre obese, Ob Obese
BMI TT A carrier
n = 37 (19.70%) n = 151 (80.30%)
UW 1 (2.71%) 3 (1.99%)
NW 5 (13.51%) 21 (13.90%)
NWO 3 (8.11%) 27 (17.88%)
PreOb 10 (27.03%) 49 (32.46%)
OB I 12 (32.43%) 23 (15.23%)
OB II 5 (13.51%) 10 (6.62%)
OB III 1 (2.70%) 18 (11.92%)
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Table 4 Anthropometric, body composition and  REE analysis for  FTO rs9939609 A  carriers vs TT genotype in  MeD 
and CTR groups
TT genotype A carriers P main 
effect of FTO 
rs9939609
P main 
effect 
of diet
P main effect 
gene‑diet 
interactionMeD CTR MeD CTR 
(n = 40) (n = 17) (n = 99) (n = 32)
Weight (kg) 0.85 0.43 0.87
 Baseline 79.63 (21.56) 73.33 (17.26) 83.29 (22.73) 78.73 (15.87)
 Change − 3.41 (6.47) − 1.27 (3.89) − 2.25 (11.79) − 0.62 (1.26)
BMI 0.92 0.33 0.81
 Baseline 29.03 (7.39) 25.74 (3.64) 30.4 (7.35) 28.50 (6.03)
 Change − 1.28 (2.34) − 0.30 (0.82) − 0.85 (4.27) − 0.18 (0.80)
Neck circumference (cm) 0.50 0.78 0.37
 Baseline 40.54 (3.39) 36.75 (3.28) 41.03 (4.19) 36.88 (3.76)
 Change − 0.60 (0.42) − 0.40 (0.96) − 1.09 (2.13) − 0.07 (1.12)
Waist circumference (cm) 0.80 0.87 0.86
 Baseline 88.17 (19.18) 86.81 (11.66) 94.14 (17.25) 87.7 (12.72)
 Change − 1.10 (3.03) − 0.78 (1.82) − 1.91 (7.55) − 1.10 (2.34)
Abdomen circumference 
(cm)
0.87 0.97 0.28
 Baseline 104.92 (18) 93.74 (9.66) 107.49 (15.9) 99.48 (14.6)
 Change − 0.80 (1.48) − 1.04 (3.46) − 3.73 (6.51) − 1.13 (2.89)
Hip circumference (cm) 0.93 0.70 0.76
 Baseline 103.8 (11.16) 102.72 (7.68) 107.68 (13.01) 107.67 (12.13)
 Change − 1.90 (4.04) − 1.38 (3.55) − 2.51 (3.93) − 1.44 (3.29)
WHR 0.80 0.89 0.89
 Baseline 0.84 (0.12) 0.84 (0.08) 0.87 (0.12) 0.82 (0.08)
 Change 0.00 (0.02) 0.00 (0.03) 0.00 (0.07) 0.00 (0.03)
R 0.10 0.98 0.87
 Baseline 533.35 (88.18) 545.31 (80.2) 484.66 (107.09) 507.77 (78.38)
 Change − 3.00 (22.26) 0.24 (33.1) 20.11 (59.77) 25.91 (42.27)
Xc 0.38 0.32 0.38
 Baseline 55.8 (11.45) 58.81 (8.83) 54.98 (15.84) 54.84 (10.33)
 Change 0.00 (4.76) − 4.53 (6.69) − 2.2 (10.33) − 2.13 (8.13)
PA 0.73 0.45 0.58
 Baseline 6.23 (1.06) 6.24 (1.22) 6.62 (1.54) 6.22 (1.07)
 Change 0.10 (0.34) − 0.40 (0.79) − 0.47 (1.57) − 0.53 (0.94)
BCM (kg) 0.17 0.91 0.94
 Baseline 27.29 (6.39) 28.95 (8.13) 31.99 (9.68) 29.66 (6.28)
 Change − 0.33 (0.98) − 0.54 (3.51) − 2.62 (7.63) − 2.75 (4.26)
Na/K 0.64 0.66 0.53
 Baseline 0.97 (0.12) 0.98 (0.13) 0.91 (0.18) 0.96 (0.13)
 Change 0.03 (0.1) 0.06 (0.1) 0.06 (0.17) − 0.12 (0.63)
TBW (L) 0.02* 0.48 0.47
 Baseline 38.36 (8.55) 38.54 (8.94) 41.76 (10.99) 39.81 (6.57)
 Change − 0.83 (1.63) 0.70 (3.04) − 1.88 (4.35) − 1.75 (3.28)
ECW (L) 0.81 0.43 0.56
 Baseline 17.23 (4.06) 17.22 (3.9) 18.01 (5.27) 17.89 (3.04)
 Change − 0.25 (1.5) 2.00 (3.26) 2.16 (6.74) 2.42 (4.07)
ICW (L) 0.65 0.92 0.81
 Baseline 21.12 (5.16) 17.22 (3.9) 23.75 (6.97) 20.59 (4.05)
 Change − 0.25 (0.74) − 0.54 (1.8) − 1.89 (4.85) − 0.95 (1.79)
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Abbreviations
ALT: alanine transaminase; AST: aspartate aminotransferase; BIA: bioelectrical 
impedence analysis; BCM: body cell mass; BCMI: body cell mass index; BFat: 
body fat mass; BLean: body lean mass; BMI: body mass index; BMC: bone min-
eral content; BMD: bone mineral density; BP: blood pressure; CDVs: cardiovas-
cular diseases; CRP: C-reactive protein; CTR : control group; DXA: dual-energy 
X-ray absorptiometry; ESR: erythrocyte sedimentation rate; ECW: extracellular 
water; FTO: fat mass and obesity-associated gene; GLM: generalized linear 
models; GPT: glutamate pyruvate transaminase; GOT: glutamic oxaloacetic 
transaminase; HWE: Hardy–Weinberg equilibrium; HCT: hematocrit; HDL: 
high-density lipoprotein; ICW: Intracellular Water; LDL: low-density lipoprotein; 
MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin 
concentration; MCV: mean corpuscular volume; MeD: Mediterranean diet; 
NW: normal-weight; NWO: normal-weight obese; Ob: obese; OR: odds ratios; 
pD: P main effect of diet; pG: P main effect of FTO rs9939609; pGD: P main 
effect gene-diet interaction; PA: phase angle; PreOb: pre obese; Xc: reactance; 
RBC: red blood cells; RDW-CV: red blood cell distribution width; R: resistance; 
REE: resting expenditure rate; SNP: single nucleotide polymorphism; NA/K: 
sodium–potassium exchange; TSI: Toscans in Italy; TBBone: total body bone; 
TBFat: total body fat mass; TBLean: total body lean mass; TBW: total body 
water; TG: triglycerides; UW: underweight; WHR: waist hip ratio; WBC: white 
blood cells; WHO: World Health Organization.
Table 4 (continued)
TT genotype A carriers P main 
effect of FTO 
rs9939609
P main 
effect 
of diet
P main effect 
gene‑diet 
interactionMeD CTR MeD CTR 
(n = 40) (n = 17) (n = 99) (n = 32)
BCMI 0.70 0.91 0.52
 Baseline 12.77 (7.02) 10.11 (1.96) 13.9 (8.08) 10.56 (1.94)
 Change − 0.10 (0.34) − 0.34 (1) − 2.40 (6.81) − 0.85 (1.23)
Android Bfat (%) 0.60 0.09 0.93
 Baseline 44.92 (12.45) 37.34 (8.78) 44.88 (12.77) 39.79 (12.61)
 Change − 4.52 (6.01) − 1.00 (2.16) − 2.96 (4.64) 0.15 (1.7)
Gynoid Bfat (%) 0.70 0.04* 0.32
 Baseline 43.51 (10.63) 36 (7.85) 41.8 ( 77(11.76) 39.07 (9.37)
 Change − 2.94 (5.14) 0.03 (1.26) − 1.67 (3.51) − 0.42 (1.74)
TBFat (%) 0.79 0.08 0.94
 Baseline 37.92 (9.45) 33.16 (6.05) 38.08 (10.34) 36.14 (9.52)
 Change − 2.74 (3.45) − 0.19 (1.14) − 2.01 (3.65) 0.31 (0.9)
Android Bfat (kg) 0.89 0.27 0.91
 Baseline 3.02 (1.96) 2.32 (1.08) 3.3 (2.17) 2.78 (1.39)
 Change − 0.47 (0.53) − 0.04 (0.27) − 0.45 (1.18) − 0.12 (0.63)
Gynoid Bfat (kg) 0.49 0.84 0.40
 Baseline 5.57 (2.19) 4.37 (1.45) 5.49 (2.58) 5.78 (1.79)
 Change − 0.62 (0.85) − 0.46 (1.25) − 0.36 (2.82) − 0.94 (2.25)
TBFat (Kg) 0.06 0.00* 0.04*
 Baseline 31.34 (14.5) 21.32 (8.66) 32.85 (15.56) 23.24 (12.11)
 Change − 3.59 (4.78) 1.93 (5.54) − 3.97 (6.97) 6.11 (9.60)
Android BLean (kg) 0.97 0.32 0.12
 Baseline 3.32 (1.01) 3.31 (0.86) 3.2 (0.91) 3.31 (0.62)
 Change − 0.22 (0.87) − 0.08 (0.15) 0.11 (0.6) − 0.08 (0.27)
Gynoid BLean (kg) 0.49 0.92 0.91
 Baseline 6.77(1.86) 7.24(2.16) 6.79(1.9) 7.08(1.26)
 Change − 0.20(1.54) − 0.18(0.31) − 0.56(5.66) 0.01(0.33)
TBLean (kg) 0.92 0.63 0.87
 Baseline 47.67(11.77) 46.47(11.84) 47.86(11.37) 47.28(8.87)
 Change − 1.23(6.82) − 0.53(1.05) − 0.56(5.66) − 0.61(2.08)
REE 0.77 0.27 0.49
 Baseline 1639.92 (409.68) 1664.96 (217.89) 1628.13 (347.37) 1583.46 (313.51)
 Change − 48.13 (327.01) − 31.44 (140.89) − 44.01 (220.32) − 7.49 (34.75)
Relationship between FTO rs9939609 A carriers and TT genotype in body composition and metabolism, according to MeD and CTR groups. Statistical significance (*) 
were given to results with p < 0.05 through GLM analysis. BMI body mass index, WHR waist hip ratio, R resistance, Xc reactance, PA phase angle, HYDR hydration, NA/K 
sodium–potassium exchange, TBW total body water, ECW extracellular water, ICW intracellular water, BFat body fat, TBFat total body fat, BLean body lean, TBLean total 
body lean, REE resting energy expenditure
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